About Juhe Biotechnology

Juhe Biotechnology develops early detection tools for gynecological cancers using DNA methylation analysis to identify critical biomarkers. Their products, including CISCER® for cervical cancer and CISENDO® for endometrial cancer, address the high mortality rates associated with late-stage diagnoses in women.

```xml <problem> Gynecological cancers, such as cervical and endometrial cancer, often have high mortality rates due to late-stage diagnoses. Current screening methods may not detect these cancers early enough, leading to poorer patient outcomes. </problem> <solution> Juhe Biotechnology develops early detection tools for gynecological cancers by analyzing DNA methylation patterns to identify key biomarkers. Their diagnostic products, including CISCER® for cervical cancer, CISENDO® for endometrial cancer, and CISOVA® for ovarian cancer, aim to improve early detection rates and ultimately reduce mortality. These tests leverage changes in DNA methylation, an epigenetic modification, which can indicate the presence of cancerous cells. By focusing on these epigenetic markers, Juhe Biotechnology offers innovative solutions for women's health. </solution> <features> - CISCER®: A diagnostic test for early detection of cervical cancer. - CISENDO®: A non-invasive screening test for endometrial cancer, designed for perimenopausal and postmenopausal women. - CISOVA®: A test for early detection of ovarian cancer. - CISVECO®: Evaluation of Reproductive Vaginal Microbiota - Utilizes DNA methylation analysis to identify cancer-specific biomarkers. - Focuses on epigenetic changes that play a critical role in tumorigenesis. - Aims to provide more stable and reliable markers for disease research compared to other sample types. </features> <target_audience> The primary target audience includes women at risk of or undergoing screening for gynecological cancers, as well as healthcare providers specializing in women's health and oncology. </target_audience> ```

What does Juhe Biotechnology do?

Where is Juhe Biotechnology located?

Juhe Biotechnology is based in Daxing, China.

When was Juhe Biotechnology founded?

Juhe Biotechnology was founded in 2020.

Location

Daxing, China

Founded

2020

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Juhe Biotechnology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

en.cispoly.com

Founded 2020 – Daxing, China

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Gynecological cancers, such as cervical and endometrial cancer, often have high mortality rates due to late-stage diagnoses. Current screening methods may not detect these cancers early enough, leading to poorer patient outcomes.

Solution

Juhe Biotechnology develops early detection tools for gynecological cancers by analyzing DNA methylation patterns to identify key biomarkers. Their diagnostic products, including CISCER® for cervical cancer, CISENDO® for endometrial cancer, and CISOVA® for ovarian cancer, aim to improve early detection rates and ultimately reduce mortality. These tests leverage changes in DNA methylation, an epigenetic modification, which can indicate the presence of cancerous cells. By focusing on these epigenetic markers, Juhe Biotechnology offers innovative solutions for women's health.

Features

CISCER®: A diagnostic test for early detection of cervical cancer.

CISENDO®: A non-invasive screening test for endometrial cancer, designed for perimenopausal and postmenopausal women.

CISOVA®: A test for early detection of ovarian cancer.

CISVECO®: Evaluation of Reproductive Vaginal Microbiota

Utilizes DNA methylation analysis to identify cancer-specific biomarkers.

Focuses on epigenetic changes that play a critical role in tumorigenesis.

Aims to provide more stable and reliable markers for disease research compared to other sample types.

Target Audience

The primary target audience includes women at risk of or undergoing screening for gynecological cancers, as well as healthcare providers specializing in women's health and oncology.